270 related articles for article (PubMed ID: 28497806)
1. Management of diffuse low-grade gliomas in adults - use of molecular diagnostics.
Buckner J; Giannini C; Eckel-Passow J; Lachance D; Parney I; Laack N; Jenkins R
Nat Rev Neurol; 2017 Jun; 13(6):340-351. PubMed ID: 28497806
[TBL] [Abstract][Full Text] [Related]
2. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Rudà R; Pellerino A; Pace A; Carapella CM; Dealis C; Caroli M; Faedi M; Bello L; Migliore E; Marchese G; Bertero L; Cassoni P; Soffietti R
J Neurooncol; 2019 Oct; 145(1):115-123. PubMed ID: 31556015
[TBL] [Abstract][Full Text] [Related]
4. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
6. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
[TBL] [Abstract][Full Text] [Related]
7. Molecular diagnostics of gliomas: the clinical perspective.
Tabatabai G; Stupp R; van den Bent MJ; Hegi ME; Tonn JC; Wick W; Weller M
Acta Neuropathol; 2010 Nov; 120(5):585-92. PubMed ID: 20862485
[TBL] [Abstract][Full Text] [Related]
8. New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status.
Shibahara I; Sonoda Y; Kanamori M; Saito R; Kumabe T; Tominaga T
Brain Tumor Pathol; 2011 Jul; 28(3):203-8. PubMed ID: 21735252
[TBL] [Abstract][Full Text] [Related]
9. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
10. Glioma.
Weller M; Wen PY; Chang SM; Dirven L; Lim M; Monje M; Reifenberger G
Nat Rev Dis Primers; 2024 May; 10(1):33. PubMed ID: 38724526
[TBL] [Abstract][Full Text] [Related]
11. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
12. [Basic principles of diagnosis and treatment of gliomas].
Wirsching HG; Weiss T; Roth P; Weller M
Nervenarzt; 2018 Jun; 89(6):692-698. PubMed ID: 29679127
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic gliomas in adults: an update.
Izquierdo C; Joubert B; Ducray F
Curr Opin Oncol; 2017 Nov; 29(6):434-442. PubMed ID: 28901965
[TBL] [Abstract][Full Text] [Related]
14. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
15. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
16. Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics.
Ruff MW; Uhm J
Curr Treat Options Oncol; 2018 Oct; 19(12):61. PubMed ID: 30361986
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
Miller JJ; Shih HA; Andronesi OC; Cahill DP
Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
[TBL] [Abstract][Full Text] [Related]
18. SEOM clinical guideline of diagnosis and management of low-grade glioma (2017).
Sepúlveda-Sánchez JM; Muñoz Langa J; Arráez MÁ; Fuster J; Hernández Laín A; Reynés G; Rodríguez González V; Vicente E; Vidal Denis M; Gallego Ó
Clin Transl Oncol; 2018 Jan; 20(1):3-15. PubMed ID: 29124520
[TBL] [Abstract][Full Text] [Related]
19. Clinical importance of molecular markers of adult diffuse glioma.
Molinari E; Curran OE; Grant R
Pract Neurol; 2019 Oct; 19(5):412-416. PubMed ID: 31175262
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]